FDA Proposal Threatens Transparency on Cancer Drug Safety and Efficacy
FDA documents have been a trove of information for researchers, leading to new insights about the safety and efficacy of a drug. An FDA proposal could end that.
Multiple Myeloma
MULTIPLE MYELOMA ADVISOR
FEATURED CONTENT
-
-
VTE Risk and Incidence in Hospitalized Patients With Blood Cancers
A new study aims to address the conundrum of coagulation risk in patients hospitalized for hematologic malignancies. -
Everyone’s Conflicted: How Open Payments Did Little to Discourage Conflicts of Interest in Oncology
Since its inception, the Open Payments act does not appear to have prompted physicians to accept fewer payments from industry overall. -
The Disappointing Reality of Crowdfunding Cancer Care
If crowdfunding doesn’t work, here’s how oncologists can help patients with financial toxicity. -
Some Targeted Therapies May Miss the Mark
Ten different drugs continued to kill cancer cells even when their target proteins were removed.
VIDEO SERIES
MULTIPLE MYELOMA NEWS
Response-Adapted Intensification in Multiple Myeloma After Suboptimal Response to Induction
Triple-Drug Induction Therapy Yields Sustained Responses in Multiple Myeloma
Hematologic Scoring System Predicts Survival in Multiple Myeloma
Treosulfan May Offer a New Standard for Prehematopoietic Stem Cell Transplantation Conditioning
Racial Disparities Affect Myeloma Treatment, Though Survival May Be Similar
Want to read more?
Please login or register first to view this content.
Next post in Multiple Myeloma
